A Novel Drug-Eluting Stent Coated With an Integrin-Binding Cyclic Arg-Gly-Asp Peptide Inhibits Neointimal Hyperplasia by Recruiting Endothelial Progenitor Cells  by Blindt, Rüdiger et al.
CA
W
P
b
R
M
C
P
A
T
c
a
s
m
s
G
T
A
M

¶
b
t
a
c
G
fi
B
2
Journal of the American College of Cardiology Vol. 47, No. 9, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
PLINICAL RESEARCH Interventional Cardiology
Novel Drug-Eluting Stent Coated
ith an Integrin-Binding Cyclic Arg-Gly-Asp
eptide Inhibits Neointimal Hyperplasia
y Recruiting Endothelial Progenitor Cells
üdiger Blindt, MD,* Felix Vogt, MD,*† Irina Astafieva, PHD,‡ Christian Fach, MD,*§
ihail Hristov, MD,†§ Nicole Krott, MSC,*† Berthold Seitz, MS,* Aphrodite Kapurniotu, PHD,
onnie Kwok, PHD,‡ Manfred Dewor, MSC, Anja-Katrin Bosserhoff, PHD,¶ Jürgen Bernhagen, PHD,¶
eter Hanrath, MD,* Rainer Hoffmann, MD,* Christian Weber, MD*†§
achen and Regensburg, Germany; and Santa Clara, California
OBJECTIVES Novel stents loaded with an integrin-binding cyclic Arg-Gly-Asp peptide (cRGD) were
analyzed for their potential to limit coronary neointima formation and to accelerate
endothelialization by attracting endothelial progenitor cells (EPCs).
BACKGROUND Re-endothelialization is important for healing after arterial injury.
METHODS Effects of cRGD on EPC number, recruitment in flow, and invasion were analyzed in vitro.
A durable polymer coating containing 67 g cRGD per stent was developed for Guidant
Tetra stents. Twelve cRGD-loaded polymer, 12 unloaded polymer, and 12 bare metal stents
were deployed in porcine coronary arteries. Quantification of cRGD in peri-stent tissue was
established by high-performance liquid chromatography (HPLC) and mass spectrometry
(MS). Histomorphometry and immunostaining were performed after 4 and 12 weeks.
Recruitment of labeled porcine EPCs was assessed 7 days after intracoronary infusion.
RESULTS The cRGD clearly supported the outgrowth, recruitment, and migration of EPCs in vitro. At
4 weeks, there was no difference for mean neointimal area and percent area stenosis in the
cRGD-loaded, polymer, or bare metal stent group. At 12 weeks, neointimal area (2.2  0.3
mm2) and percent area stenosis (33 5%) were significantly reduced compared with polymer
stents (3.8  0.4 mm2, 54  6%; p  0.010) or bare metal stents (3.8  0.3 mm2, 53  3%;
p  0.001). The HPLC/MS confirmed cRGD tissue levels of 1 to 3 g/stent at 4 weeks,
whereas cRGD was not detectable at 12 weeks. Staining for CD34 and scanning electron
microscopy indicated enhanced endothelial coverage on cRGD-loaded stents at 4 weeks
associated with a significant increase in the early recruitment of infused EPCs.
CONCLUSIONS Stent coating with cRGD may be useful for reducing in-stent restenosis by accelerating
endothelialization. (J Am Coll Cardiol 2006;47:1786–95) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.081of Cardiology Foundation
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ghe introduction of first-generation drug-eluting stents has
learly reduced the incidence of in-stent restenosis (ISR)
fter percutaneous coronary intervention, which has repre-
ented the Achilles heel of interventional cardiology for
ore than a decade. Several multi-center clinical trials have
hown the superiority of drug-eluting stents compared with
From the *Department of Cardiology, University Hospital Aachen, Aachen,
ermany; †Interdisciplinary Center for Clinical Research in Biomaterials and
issue-Material Interaction in Implants BIOMAT, University Hospital Aachen,
achen, Germany; ‡Guidant Corporation, Santa Clara, California; §Department of
olecular Cardiovascular Research, University Hospital Aachen, Aachen, Germany;
Institute of Biochemistry, University Hospital Aachen, Aachen, Germany; and the
Institute of Pathology, University of Regensburg, Regensburg, Germany. Supported
y a grant from the Interdisciplinary Center for Clinical Research “BIOMAT” within
he faculty of medicine at the RWTH Aachen University. Drs. Astafieva and Kwok
re full-time employees of Guidant Corporation, Santa Clara, California, and
ontributed to the development of the stent coating. The stents were delivered by
uidant Corporation, which was part of a research cooperation; there was no other
nancial or nonfinancial support exceeding the stent manufacturing process. Drs.
lindt and Vogt contributed equally to this work.o
Manuscript received July 28, 2005; revised manuscript received November 22,
005, accepted November 30, 2005.are metal stents to reduce major cardiac events after
ercutaneous coronary intervention (1,2). Based on these
ata, the frequency of angiographic restenosis for the
urrently available drug-eluting stents range from 8% to
5% depending on the case or lesion complexity (3). The
emaining cases of ISR might be explained by the limita-
ions of the drugs in use, i.e., sirolimus and paclitaxel, which
ainly act by inhibition of smooth muscle cell (SMC)
roliferation. Thus, ISR still constitutes a significant prob-
em given the large volume of coronary interventions and
xpanding indications (4).
The pathophysiology of neointimal hyperplasia in ISR
omprises complex interactions between cellular and acel-
ular elements of the vessel wall and the blood (5). It has
een shown that a functionally intact endothelium is a prereq-
isite for the inhibition of neointimal growth after percuta-
eous coronary intervention (6), and that endothelial pro-
enitor cells (EPCs) can be recovered from a peripheral pool
f mononuclear cells (7). The EPCs have been characterized
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May 2, 2006:1786–95 Proendothelial Stent Coating With cRGDy the expression of stem cell (CD133, CD34) and endo-
helial cell markers (vascular endothelial growth factor
VEGF] receptor 2, CD31, VE-cadherin, von Willebrand
actor), and by their ability to develop colony-forming units
8,9). The contribution of EPCs to re-endothelialization
fter vascular injury has recently been shown. For example,
nfusion of EPCs after vascular injury and their mobilization
nd incorporation after statin treatment significantly re-
uced neointimal growth (10,11); however, the knowledge
bout homing and differentiation of EPCs at sites of injury
emains incomplete. In studies with hematopoietic stem
ells, a crucial role in these processes has been ascribed to
ntegrins (12), a family of transmembrane adhesion recep-
ors, which regulate cell phenotype and function and display
pecific binding and signaling properties (13). In prior
tudies, expression of integrins with integrin-binding cyclic
rg-Gly-Asp peptide (cRGD) binding motifs has been
hown on EPCs (10,12). The RGD sequence is recognized
y a variety of integrins, including v3, 51, v1,
v5, and IIbIII, and is found in a variety of extracellular
atrix components. According to the stereochemistry of the
equence Arg-Gly-Asp-Xaa, the binding specificity to the
ntegrins can be controlled (14).
Thus, the goal of this study was to explore the potential
f a hydrophilic cRGD peptide with a higher affinity for the
v3- than the 51-integrin receptor (15) to reduce
eointimal hyperplasia by facilitating recruitment of circu-
ating EPCs and endothelialization. Hence, the capacity of
he cRGD to effectively attract EPCs was evaluated using a
ewly developed polymer stent loaded with the cRGD. It
hould be analyzed whether local delivery of cRGD was
apable of mediating the attraction of EPCs and enhanced
oronary endothelialization, thus significantly reducing neo-
ntimal hyperplasia after stent implantation.
ETHODS
solation and culture of EPCs and SMCs. Peripheral
lood mononuclear cells were separated by density gradient
Abbreviations and Acronyms
BSA  bovine serum albumine
CIC  chronic inflammatory cells
cRGD  integrin-binding cyclic Arg-Gly-Asp
peptide
DiI-Ac-LDL  1,1=-dioctadecyl-3,3,3=,3=-
tetramethylindocarbocyanine-labeled
Ac-low-density lipoprotein
EPC  endothelial progenitor cell
HPLC  high-performance liquid
chromatography
ISR  in-stent restenosis
MS  mass spectrometry
RP  reverse-phase
SMC  smooth muscle cell
VEGF  vascular endothelial growth factorentrifugation from porcine blood. Isolated peripheral blood aononuclear cells were seeded in culture flasks with differ-
nt coatings: either 1% bovine serum albumin, or 10 g/ml
uman fibronectin, or 1 g/ml and 100 g/ml cRGD
eptide (cyclic GPenGRGDSPCA with Pen indicating
enicillamine, enabling a cyclic structure by disulfide bond
ormation with the cysteine and increasing the conforma-
ional restraints on the ring structure [14], relative molecular
eight: 948.05) in microvascular endothelial growth me-
ium. After seven days, isolated cells were subjected to
ytochemical analysis, study under flow conditions, or inva-
ion experiments. The SMCs were isolated and cultured as
escribed (16,17).
haracterization and number of EPCs. For uptake of
,1=-dioctadecyl-3,3,3=,3=-tetramathylindocarbocyanine-
abeled Ac-low-density lipoprotein (DiI-Ac-LDL), periph-
ral blood mononuclear cell-derived EPCs were incubated
ith DiI-Ac-LDL and fluoresceinisothiocyanat-labeled
lex europaeus agglutinin I. The DiI-Ac-LDL/lectin
ouble-positive cells were judged as EPCs, and the percent-
ge of DiI-Ac-LDL/lectin double-positive cells was ana-
yzed by flow cytometry.
nalysis of EPC attachment under flow conditions. The
PC adhesion on bovine serum albumine (BSA), fibronec-
in (10 g/ml), or surface-immobilized cRGD-peptide (1
g/ml or 100 g/ml) was quantified under flow conditions
sing a parallel plate flow chamber as described (18,19).
uspensions of EPCs were perfused, and the number of
PCs firmly adherent by primary interaction with the
ifferent matrices was quantified.
nvasion assay. Invasion assays were performed in a mod-
fied Boyden chamber as described (16,17). Filters were
oated with a reconstituted basement membrane, the lower
ompartment was filled with Dulbecco modified eagle
edium with or without cRGD peptide (100 g/ml), and
MCs or EPCs were placed in the upper compartment.
fter incubation, adherent cells were counted.
tent design and polymer coating. A new polymer stent
oating was developed and subsequently applied to the stents
stainless steel Multi-Link Guidant Tetra stent [Santa Clara,
alifornia], 3-mm diameter, 13-mm length, 5.15 g
RGD/mm stent length). The polymer coating fulfilled the
equirements for appropriate local drug delivery of the hydro-
hilic cRGD peptide. It consisted of an adherent, conformal,
echanically robust coating based on an aromatic poly-
therurethaneurea with a soft segment of polytetramethyl-
neoxide and a hard segment of diphenylmethane diisocyanate
nd mixed diamines (BioSpan SPU, Polymer Technology
roup, Berkeley, California) covered by a control-release layer.
n vitro and in vivo pharmacokinetic studies. Cumulative
RGD release was measured after simulated use of peptide-
oaded stents by high-performance liquid chromatography
HPLC) in vitro. For in vivo pharmacokinetics, stents were
sed 4 and 12 weeks after implantation. Adjacent tissue was
issected as described (20), pre-processed, and subjected to
everse-phase (RP)-HPLC and mass spectrometry (MS)
nalysis of cRGD.
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Proendothelial Stent Coating With cRGD May 2, 2006:1786–95nimal model. Twelve polymer-coated cRGD-loaded, 12
nloaded polymer, and 12 stainless steel bare metal stents
ere deployed into the right and left coronary arteries of 18
omestic pigs (9 pigs per time point; 2 stents per animal; 6
tents per group). The stents were implanted using an
ncomplete factorial design, thus allowing intraindividual
nd interindividual comparisons, and the pigs were ran-
omly assigned to these treatment modalities. The stent-
o-artery ratio was 1.1 to 1.2, with similar ratios in all
roups. Pigs were maintained on 75 mg clopidogrel and 100
g aspirin per day and killed after 4 or 12 weeks. Thus, 6
tents of each type were subjected to histology at each time
oint. In an additional group of pigs, histologic assessment
as combined with intravascular ultrasound analysis at 4
nd 12 weeks: 4 stents of each type were implanted into 6
igs (3 pigs per time point; 2 stents per animal; 2 stents per
roup). Thus, in total, 8 stents of each type were implanted
er time point and group. Further animals were instru-
ented for in vivo drug elution (6 cRGD-loaded and 6
nloaded polymer stents were individually implanted into
2 pigs; 3 stents per group and time point), EPC injection
4 stents of each type implanted into 4 pigs; 3 stents per
nimal), and scanning electron microscopy experiments (3
tents of each type implanted into 3 pigs; 3 stents per
nimal).
ntracoronary infusion of labeled EPCs. Isolated porcine
PCs were detached with Accutase (PAA Laboratories,
asching, Austria) and labeled with cell tracker CM-DiI (1
g/ml, Molecular Probes-Invitrogen, Karlsruhe, Germany).
abeled EPCs (3 107) were infused into coronary arteries
mmediately after stent implantation. After seven days, pigs
ere killed, stents were explanted, and after opening by a
ongitudinal cut, the luminal area was inspected by en face
uorescence microscopy. The number of DiI-labeled cells
as determined in all microscopic fields of the complete
tent surfaces and compared with unloaded polymer and
are metal control stents. The area with specific EPC-
erived positive DiI fluorescent labeling per stent was also
etermined by image analysis using AnalySIS software (Soft
maging System, Münster, Germany) and expressed in
m2/stent.
istomorphometric and histopathologic evaluation and
mmunohistochemistry. The arteries were sectioned into
- to 5-mm segments and embedded in Technovit 9100
ew (Heraeus Kulzer GmbH, Wehrheim, Germany). Then,
0- to 12-m sections from the proximal, middle, and distal
art of the stents were prepared and stained. Five millime-
ers of peri-stent tissue from both sides of the stent were
mbedded in paraffin, sectioned (5 m), and subjected to
mmunostaining as described (20). Lumen area, neointimal
hickness, and internal and external elastic lamina areas were
easured. Neointimal area was defined as external-internal
amina area, and percent cross-sectional area stenosis was
efined as (1  [lumen area/internal elastic lamina area] 
00%). The statistical analysis for treatment effects was
onducted based on the average of all sections per stent. The anflammatory response to the polymer was analyzed by
ounting of chronic inflammatory cells (CIC) comprising
acrophages, lymphocytes, and neutrophils, recognized
y their typical morphology. For each tissue section, five
igh-power fields around the stent struts were randomly
hosen and the number total of CICs was assessed. Fibrin
eposition was analyzed by Ladewig staining. Immuno-
taining was performed as described (20). Anti-CD34 was
sed as primary antibody; for detection, an horse radish-
eroxidase-conjugated secondary antibody was applied.
egative controls were carried out with nonimmune immu-
oglobulin G.
canning electron microscopy. The specimens were fixed
n 3% glutardialdehyde for at least 1 h. They were dehy-
rated in a graded acetone series (30, 50, 70, 90, 3 100%)
nd critical-point-dried in carbon dioxide. The samples
ere fixed on specific stubs and sputter-coated with gold
SCD 030, Balzers Union), then investigated in an ESEM
L 30 FEG (FEI-Philips, Kassel, Germany) in high-
acuum mode.
tatistical analysis. All results are expressed as mean 
EM. For the in vitro experiments, statistical significance
as evaluated using unpaired Student t test or analysis of
ariance followed by the Dunnett post-hoc test for more
han two means. For histomorphometric measurements, the
ruskal-Wallis test was used to determine overall statistical
ignificance, followed by the Mann-Whitney U test with
onferroni correction for subsequent pairwise comparison if
he overall significance was 0.05; p values  0.05 were
onsidered significant.
ESULTS
he effect of cRGD on the outgrowth of EPCs. To
nvestigate the effect of surface-bound cRGD on the out-
rowth of EPCs, the number and the morphology of cells
ound to the peptide were determined in vitro. After seven
ays in culture, the occurrence of cells with a typical
pindle-shaped phenotype could be observed (Fig. 1A).
dherent cells were harvested and identified as EPCs by
iI-Ac-LDL/lectin double staining using flow cytometry.
ore than 90% of adherent cells were identified as double-
ositive, i.e., EPCs (Fig. 1B). The coating with different
oncentrations of cRGD resulted in an increase in the
umber of EPCs by 163  9% at 1 g/ml (p  0.007) and
y 170  11% at 100 g/ml (p  0.003), compared with
ontrols without cRGD (Fig. 2A). No significant difference
n cell number increase was found between EPCs cultured
n cRGD or fibronectin (167  10% vs. cRGD at 100
g/ml, p  0.765).
ecruitment of EPCs by cRGD under flow condi-
ions. To determine the effect of cRGD on EPC recruit-
ent under flow conditions, porcine EPCs were perfused at
shear rate of 3 dynes/cm2 in a parallel-wall flow chamber.
lthough few EPCs displayed transient rolling interactionfter initial tethering on cRGD, most EPCs underwent
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May 2, 2006:1786–95 Proendothelial Stent Coating With cRGDmmediate arrest resulting in stable adhesion. Much weaker
rrest was seen on BSA-coated plates (Fig. 2B). Coating
ith cRGD resulted in a significant increase of shear-
esistant EPC arrest (159  7% at 1 g/ml, p  0.04; 164 
% at 100g/ml, p 0.009; both vs. BSA control), which was
omparable with fibronectin-mediated arrest (164  9% vs.
RGD at 100 g/ml, p  0.814).
ffects of cRGD on the invasive potential of EPCs and
MCs. The potential of cRGD to act as a chemoattractant
or EPCs or SMCs was determined using a modified
igure 1. Characterization and outgrowth of isolated porcine endothelial
rogenitor cells (EPCs). (A) Mononuclear cells were plated on culture
ishes in the presence (1 g/ml or 100 g/ml, respectively) or absence of
ntegrin-binding cyclic Arg-Gly-Asp peptide (cRGD) coating. Coating
ith cRGD provoked a significant dose-dependent increase of spindle-
haped cells compared with uncoated control experiments. Representative
mages from four isolations are shown, magnification 100. (B) Flow
ytometry analysis of adherent cells at day 7 of culture. Unstained cells
erved as a control condition. Analysis was performed by manual gating
nd fluorescence channel (FL)-1/FL-2 dot plot quadrant statistic.
,1=-dioctadecyl-3,3,3=,3=-tetramethylindocarbocyanine-labeled Ac-low-
ensity lipoprotein/lectin double-positive cells in the upper right region
ere judged as EPCs. FITC  fluoresceinisothiocyanat.oyden chamber. The EPCs were used after distinct peri-
u
cds of culture (5 and 12 days). For both subgroups, cRGD
ignificantly stimulated the invasion of EPCs (209 35% of
ontrol at 5 days, p 0.021, 355 45% of control at 12 days,
 0.0001) (Fig. 3A). In contrast, cRGD did not stimulate
he invasive potential of SMCs (p  0.196) (Fig. 3B).
tent characteristics and in vitro pharmacokinetics. The
PLC analysis of cRGD enabled its detection with linear-
ty across a range of concentrations (1 to 100 g/ml).
tability of the peptide dissolved in phosphate-buffered
aline was shown from 4°C to 37°C and for up to 10 days
data not shown). After incorporation of the peptide into
he polymer matrix of the stents, electron microscopy
howed complete surface integrity after crimping onto
elivery system catheter, after passing through a guiding
atheter, and after subsequent stent expansion in
hosphate-buffered saline (simulated use) (Fig. 4A). In vitro
rug release of cRGD-loaded stents (n  3) showed an
xponential release profile over at least 72 h. After 72 h, 52%
f the cRGD load (35 of 67 g) had been eluted, so that a
ontinuous release thereafter can be assumed (Fig. 4B).
igure 2. Recruitment of isolated endothelial progenitor cells (EPCs) on
ntegrin-binding cyclic Arg-Gly-Asp peptide (cRGD) matrix. (A) After 7
ays in culture, adherent cells were counted in multiple microscopic fields.
oating with cRGD (1 g/ml or 100 g/ml) resulted in a significant
ncrease in EPC outgrowth compared with uncoated control experiments.
he fibronectin coating served as a positive control condition (n  4, *p 
.05). (B) Coating with cRGD (1 g/ml or 100 g/ml) resulted in a
ignificant increase in EPC arrest under flow conditions compared with
ncoated control experiments. The fibronectin coating served as a positive
ontrol condition (n  4, *p  0.05). FN  fibronectin.
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Proendothelial Stent Coating With cRGD May 2, 2006:1786–95elease profiles were similar for unexpanded and expanded
tents (data not shown).
n vivo pharmacokinetics. Tissue levels of cRGD were
nalyzed by RP-HPLC and MS to confirm whether the
bserved biological effects correlated with cRGD levels in
he adjacent vascular wall. A procedure was established
llowing the detection of cRGD from complex tissue
ysates. On optimization, it was possible to recover and
etect cRGD spiked into 200 mg of tissue lysate. The
P-HPLC analysis of tissue lysates from unloaded stents
id not yield any peaks at or near the elution volume of
RGD (Fig. 5A). Recovery of cRGD from the tissue
urrounding the stent was determined and compared be-
ween 4 and 12 weeks. The RP-HPLC analysis showed that
mall amounts (1 to 3 g) of a peptide peak with a
olecular mass 3 kDa were detected in tissue lysates
xcised after 4 weeks (Fig. 5B). Externally added (“spiked”)
RGD eluted at the same volume, indicating that the
igure 3. Effect of the integrin-binding cyclic Arg-Gly-Asp peptide
cRGD) on endothelial progenitor cell (EPC) and smooth muscle cell
SMC) invasion. (A) cRGD (100 g/ml) stimulated significantly the
nvasive potential of EPCs compared with control cells, whereas SMC
nvasion against different concentrations of cRGD was not altered (B).
MEM  Dulbecco’s modified eagle medium.ecovered peptide was cRGD (Fig. 5B). Identity of recov-
s
1red cRGD was finally confirmed by MS analysis (Figs. 5C
nd 5D). The mass of the isolated peptide species from
issue samples was 474.5 Da, and thus was identical to that
f pure standard cRGD (M2 mass of 474.8  0.3 Da)
Fig. 5C). In addition, an identical mass was obtained when
RGD was spiked into a raw control tissue lysate that
nderwent an identical procedure (Fig. 5D). Thus, cRGD
as efficiently released from stents into the adjacent tissue
nd measurable cRGD levels were present in the tissue after
our weeks. In contrast, after 12 weeks, tissue lysates did not
ontain detectable cRGD (data not shown).
istomorphometric measurements. All vessels were an-
iographically and histologically patent at all time points.
tent malapposition was not detectable in histologic speci-
ens or by intravascular ultrasound examination after stent
eployment (Fig. 6A). At 4 weeks, cross-sectional area
tenosis was 35  4%, 31  2%, and 36  4% for unloaded
olymer, cRGD-loaded polymer, and bare-metal stents,
espectively (p 0.674). Mean neointimal areas were 2.5
.3 mm2, 2.3  0.2 mm2, and 2.6  0.2 mm2 (p  0.268),
nd neointimal thickness was 0.41 0.05 mm, 0.31 0.04
m, and 0.42 0.05 mm (p 0.310); mean internal elastic
amina areas were 7.2  0.2 mm2, 6.9  0.3 mm2, and
.3  0.3 mm2 (p  0.462), and mean external elastic lamina
reas were 8.2  0.2 mm2, 7.9  0.3 mm2, and 8.2  0.3
m2 (p  0.696) for unloaded polymer, cRGD-loaded
olymer, and bare-metal stents, respectively. At 12 weeks,
ross-sectional area stenosis of the cRGD-loaded stents was
igure 4. Stent design, mechanical properties, and in vitro integrin-
inding cyclic Arg-Gly-Asp peptide (cRGD) release from the stent. (A)
canning electron microscopy photographs showing smooth surfaces of the
olymer stent coating after complete expansion of the stent and after
imulated use (magnification in the left panel 10, in the right panel
00). (B) The cRGD-coated stent release kinetic profile over 72 h.
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May 2, 2006:1786–95 Proendothelial Stent Coating With cRGDignificantly lower (33  5%) as compared with unloaded
olymer or bare-metal stents (54  6% and 53  3%, p 
.010 and p  0.001, respectively), whereas no differences
ere observed between unloaded polymer and bare-metal
tents (p  0.744). The corresponding mean neointimal
reas and neointimal thicknesses were 3.8 0.4 mm2, 2.2
.3 mm2, and 3.8  0.2 mm2 (p  0.001 for cRGD-loaded
s. unloaded and for cRGD-loaded vs. bare-metal, respec-
ively; p  0.657 for unloaded vs. bare-metal) and 0.67 
.06 mm, 0.39  0.05 mm, and 0.72  0.05 mm
p  0.006 for cRGD-loaded vs. unloaded, p  0.001 for
RGD-loaded vs. bare-metal, and p  0.295 for unloaded
igure 5. In vivo recovery of integrin-binding cyclic Arg-Gly-Asp pe
uantification of cRGD vascular tissue levels. (A) The high-performance
ysate surrounding an unloaded polymer stent implanted for 4 weeks and co
tent. The spectrum from the cRGD-containing and cRGD-free tissue ly
issue lysate (blue), a peak is visible at an elution time around 16.2 min that
ure cRGD peptide alone underwent chromatography (red). Only the r
ubstances with a relative molecular weight (Mr)  3,000 Da was obtained
weeks after stent implantation. The HPLC chromatogram obtained fro
eeks (green). After separation of the tissue from the stent, the tissue
hromatography as an HPLC standard (red). The two lysates show a pea
issue with cRGD leads to a higher peak and shows the chromatographic id
eaks are indicated by arrows. (C) Identification of the recovered implanted
issue lysate surrounding the cRGD-loaded 4-week implanted stent was det
green spectrum in B) was isolated and lyophilized, and the cRGD identi
s indicated. (D) Confirmation of stent-derived cRGD identification by E
RGD before work-up (which was identical to that as described in panel
t the same Mr as in (C).s. bare-metal) for unloaded polymer, cRGD-loaded poly- per, and bare-metal stents, respectively. Mean internal
lastic lamina areas at 12 weeks were 7.4  0.2 mm2, 7.0 
.1 mm2, and 7.3  0.2 mm2 (p  0.531), mean external
lastic lamina areas were 8.4  0.2 mm2, 8.4  0.1 mm2,
nd 8.3  0.2 mm2 for unloaded polymer, cRGD-loaded,
nd bare-metal stents, respectively (p  0.871). Injury
cores did not differ among the groups. All histomorpho-
etric data are summarized in Table 1.
istopathologic analysis. Only mild infiltration with CIC
as observed around the stent struts, indicating a sufficient
iocompatibility of the polymer. Inflammation rates were
imilar in all three stent groups at 4 and 12 weeks (unloaded
(cRGD) from vascular tissues surrounding cRGD-loaded stents and
chromatography (HPLC) chromatogram obtained from a vascular tissue
ed with a tissue lysate that was spiked with cRGD after removal from the
re essentially superimposable. In the preparation from the cRGD-spiked
ely co-elutes with the standard cRGD peak (black). As an HPLC control,
t part of the spectrum is shown, but overall, only a limited number of
r not shown). (B) Recovery of cRGD from the surrounding vascular tissue
ascular tissue lysate surrounding the cRGD-loaded stent implanted for 4
ysed and spiked with additional cRGD (blue). Pure cRGD underwent
elutes at the same time (at 16 min) as the standard cRGD. Spiking the
y of the spiked cRGD species with that loaded onto the stent. The cRGD
D by electrospray ionization mass spectrometry analysis. The cRGD from
by HPLC (see B), the assumed cRGD-containing HPLC peak at 16 min
verified by MS analysis. The M2 peak of cRGD was clearly detectable
S of the spiked tissue lysate. The tissue lysate was spiked with additional
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Proendothelial Stent Coating With cRGD May 2, 2006:1786–95eeks: 35  8 CIC/field, 33  4 CIC/field, or 39  6
IC/field, p 0.475; at 12 weeks: 34 8 CIC/field, 38 10
IC/field, or 40 9 CIC/field, p 0.901) (Fig. 6B). In vessel
igure 6. Histomorphometric analysis. (A) Representative photomicro-
raphs of coronary tissue sections that were used to determine stenosis rates
fter implantation of unloaded polymer, integrin-binding cyclic Arg-Gly-
sp peptide (cRGD)-loaded, or bare-metal stents after 4 and 12 weeks
magnification 40). L  lumen; NI  neointima; arrows indicate
eointimal area. (B) Quantification of infiltration with chronic inflamma-
ory cells (CIC) around the stent struts.
able 1. Histomorphometric Data
Unloaded
Polymer Stents
weeks (n  8 per group)
Percent cross-sectional area stenosis (%) 35  4
Lumen area (mm2) 4.6  0.4
Neointimal area (mm2) 2.5  0.3
Neointimal thickness (mm2) 0.41  0.05
Internal elastic lamina area (mm2) 7.2  0.2
External elastic lamina area (mm2) 8.2  0.2
Injury score 1.4  0.2
2 weeks (n  8 per group)
Percent cross-sectional area stenosis (%) 54  6
Lumen area (mm2) 3.5  0.5
Neointimal area (mm2) 3.8  0.4
Neointimal thickness (mm2) 0.67  0.06
Internal elastic lamina area (mm2) 7.4  0.2
External elastic lamina area (mm2) 8.4  0.2
Injury score 1.6  0.2Statistically significant.
cRGD  integrin-binding cyclic Arg-Gly-Asp peptide; NS  not significant.egments distant to the stent struts, no relevant inflammatory
nfiltration was seen. In contrast to sirolimus- and paclitaxel-
luting stents (21), no peri-stent fibrin deposition (a marker of
tent-induced injury healing) was identified in any of the stent
roups (data not shown). To evaluate the in vivo effects of
RGD coating on EPC recruitment, stent coverage by circu-
ating progenitor cells was assessed by CD34 staining, electron
icroscopy, and the presence of DiI-labeled porcine EPCs
njected into the coronary artery directly after stent implanta-
ion (Fig. 7). At 4 weeks, the cRGD-loaded stents were lined
y 83  3 CD34 cells/field, whereas only 35  2 and 36 
CD34 cells/field were observed in the unloaded polymer
nd bare metal stent group (p  0.020 for cRGD-loaded vs.
nloaded stents, p  0.021 for cRGD-loaded vs. bare-metal
tents) (Figs. 7A and 7B). This was also illustrated by electron
icroscopy (Fig. 7C). At 12 weeks, stent coverage was com-
lete in all groups without significant differences (87 8, 95
, or 93  3 CD34 cells/field for unloaded polymer,
RDG-loaded polymer, or bare metal stents, respectively; p
.585). Moreover, intracoronary injection of DiI-labeled EPCs
t the time of stent placement showed their preferential
ecruitment to cRGD-loaded (fluorescent labeling: 1.3518 
.2257 mm2/stent, p 0.027 for cRGD vs. unloaded polymer
tents, p 0.006 for cRGD vs. bare metal stents; cell counting:
2.5  1.4% of high-power fields containing DiI-labeled
PCs, p 0.037 for cRGD vs. unloaded polymer stents, p
.046 for cRGD vs. bare metal stents) but not control stents
fluorescent labeling: 0.2419  0.1522 and 0.2156  0.1802
m2/stent; cell counting: 2.5 0.3% and 3.3 0.8% positive
igh-power fields for unloaded polymer and bare-metal stents,
espectively) (Figs. 7D and 7E).
ISCUSSION
he present study shows that a cyclic RGD peptide with
v3-integrin-binding capacities can: 1) stimulate out-
rowth, shear-resistant recruitment, and invasion of EPCs,
cRGD-Loaded
Polymer Stents
Bare-Metal
Stents p Value
31  2 36  4 0.674 (NS)
4.7  0.3 4.7  0.4 0.999 (NS)
2.3  0.2 2.6  0.2 0.268 (NS)
0.31  0.04 0.42  0.05 0.310 (NS)
6.9  0.3 7.3  0.3 0.462 (NS)
7.9  0.3 8.2  0.3 0.696 (NS)
1.5  0.1 1.4  0.2 0.903 (NS)
33  5 53  3 0.002*
4.9  0.4 3.5  0.3 0.042*
2.2  0.3 3.8  0.2 0.001*
0.39  0.05 0.72  0.05 0.002*
7.0  0.1 7.3  0.2 0.531 (NS)
8.4  0.1 8.3  0.2 0.871 (NS)
1.6  0.3 1.5  0.2 0.918 (NS)
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May 2, 2006:1786–95 Proendothelial Stent Coating With cRGDigure 7. Effects on endothelialization. (A) Representative photomicrographs of endothelialization, analyzed by CD34 staining, of unloaded polymer,
ntegrin-binding cyclic Arg-Gly-Asp peptide (cRGD)-loaded, or bare-metal peri-stent tissue sections after 4 and 12 weeks (magnification 400). (B)
uantification of endothelialization of unloaded polymer, cRGD-loaded, or bare-metal persistent tissue sections. (C) Electron microscopy of cRGD stent surfaces
t 4 weeks showed uniform and complete endothelial coverage (left), whereas analysis of control stents showed incomplete endothelial coverage in the interstrut
egion. (D) The cRGD coating (left) significantly increased endothelial progenitor cell (EPC) recruitment as compared with control stents (right, magnification
00). (E) Quantification of 1,1=-dioctadecyl-3,3,3=,3=-tetramethylindocarbocyanine (DiI)-labeled EPCs by fluorescent image analysis (top) or cell counting
bottom).
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Proendothelial Stent Coating With cRGD May 2, 2006:1786–95) reliably be incorporated into and released from a newly
esigned polymer stent coating, and thereby, 3) significantly
nhibit the extent of neointimal hyperplasia by accelerating
tent endothelialization.
Endothelial denudation is considered to be the primary
njury after balloon angioplasty and stent implantation. When
arger areas are denuded or endothelial recovery is delayed, a
igher degree of intimal thickening ensues (22). Furthermore,
t could be shown that conditioned serum of injured endothe-
ial cells can stimulate proliferation and migration of SMCs
23). Several studies have also highlighted the importance of
one marrow-derived EPCs for the process of healing after
ascular injury. For instance, the number of circulating EPCs
s significantly increased after myocardial infarction (24). Evi-
ence showing that EPCs can also be used as a therapeutic
pproach to accelerate re-endothelialization after injury has
ecently been provided (11). Treatment with statins and the
nhibition of pro-migratory factors have implicated the recruit-
ent of EPCs in accelerating endothelial recovery and reduc-
ng neointima (25). Similarly, accelerated re-endothelialization
y local transfer of the VEGF-2 plasmid or by statin therapy
as been shown to inhibit neointima formation likely by
ncreasing the mobilization and incorporation of EPCs (26).
evertheless, the mechanisms underlying EPC recruitment
homing) to the site of injury remain to be elucidated. Al-
hough the blockade of the keratinocyte-derived chemokine
eems to enhance neointimal formation by delaying endothelial
ecovery (22), this effect may in part be attributable to inter-
erence with the recruitment and incorporation of EPCs.
For this study, cRGD characterized by higher affinity for
v3 than 51 integrins (15) was incorporated into a
pecifically designed stent and evaluated for its ability to
ecruit EPCs and to reduce neointimal hyperplasia. For
ematopoietic progenitor cells, earlier studies have sug-
ested a role of integrins in supporting cell adhesion (27).
lthough SMC outgrowth cells from peripheral blood have
een shown to preferentially express 1 integrins binding to
bronectin (10), coating with cRGD seemed to attract
redominantly CD34 EPCs. The results presented herein
ould be consistent with the notion that EPCs express
v3 at higher levels than SMC progenitors. In vitro
solation and culture of EPCs on cRGD also resulted in an
ncreased outgrowth of EPCs. In addition, the effect of
RGD in promoting EPC adhesion could also be evidenced
n a model simulating flow conditions in human arteries
28). Finally, an established Boyden chamber model showed
hat cRGD does not solely stimulate recruitment of EPCs
o cRGD-coated surfaces, but also acts as a chemoattractant
or EPCs to induce their transmigration. Notably, nonqui-
scent SMCs showed a lesser responsiveness to cRGD in a
ide-by-side analysis of their invasive potential. Thus, this
ndeed seems to be attributable to a higher expression of
v3 integrin on EPCs as compared with SMC progenitors
29). Moreover, these results are in accordance with findings
hat the systemic application of cRGD abrogates accelerated
ndothelialization and incorporation of EPCs (10), presum- tbly by disrupting a haptotactic gradient formed by RGD-
ontaining matrix components.
A major challenge in the present study was to confer the
otential benefit of cRGD to a stent system in vivo. The
ontrolled elution of sufficient amounts of hydrophilic
eptides has not yet been established. Drug-eluting stents
hown to be effective in animal models and clinical trials to
ate have typically incorporated hydrophobic substances
30,31). A stent coating in our study was designed to enable
he elution of 67 g cRGD over more than 72 h after
imulated use and expansion of the stent. The HPLC and
iquid chromatography-MS confirmed the presence of
RGD in the tissue surrounding the stent at 4 weeks.
oreover, this was sufficient to successfully attract infused
orcine EPCs, as well as endogenous CD34 cells for
ffective re-endothelialization. Our results clearly showed
hat the initial recruitment of infused EPCs from the
irculation was markedly increased on cRGD-loaded versus
ontrol stents. Taken together with the improved coverage
s shown by CD34 staining at later time points (4 and 12
eeks), our data show that loading with cRGD acts to
ccelerate re-endothelialization by recruiting circulating
PCs. Moreover, the results are in accordance with those
rom a recent clinical trial using a CD34 antibody-coated
tent for effective improvement of endothelialization (32).
eyond promoting endothelialization to limit neointimal
rowth, the mobilization of EPCs has been nicely correlated
ith an increase in segmental NO production after place-
ent of VEGF-2 gene-eluting stents (26), suggesting that
he increased EPC recruitment in cRGD-coated stents may be
ccompanied by a similar improvement of endothelial function.
Finally, the cRGD-loaded polymer stents were tested
sing a well-established porcine animal model of arterial
njury in which the 3-month post-stent follow-up is com-
arable with 12 to 18 months of follow-up data in humans
33). Results presented here indicate a long-term protective
ffect of local cRGD delivery on neointimal hyperplasia.
mportantly, the polymer showed an excellent biocompat-
bility in vivo and did not enhance neointimal hyperplasia by
tself compared with bare metal stents, and the duration of
ffect extended beyond that seen in a similar model using
irolimus-eluting stents (21). However, because all data and
arameters obtained were collected in an animal model
ithout major spontaneous atherosclerosis, the conclusions
rawn might only apply to nondiseased arteries.
The apparent discrepancy in the efficacy of the cRGD
tents between 4 and 12 weeks may be explained by the
nding that neointimal growth in pigs and humans can
ontinue at later time points amounting to a maximum at 3
onths (34), as evident by a difference between 4 and 12
eeks in our control groups. This corresponds to the notion
hat the time course of re-endothelialization in pig models
eported by different groups may substantially vary (6). The
se of electron microscopy as a sensitive technology for the
etection of (not) endothelialized stent segments enabled us
o confirm that re-endothelialization was indeed not com-
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May 2, 2006:1786–95 Proendothelial Stent Coating With cRGDlete at four weeks and thus may rather be delayed to later
ime points in our model. Hence, the benefit of endotheli-
lization in inhibiting neointimal growth (e.g., by limiting
MC recruitment and proliferation) may only be fully
ccomplished when endothelial recovery has almost been
ompleted at time points later than four weeks. Because
ndothelialization at four weeks was further improved on
RGD versus control stents in our study, concomitant with
he recruitment of EPCs supported by the in vitro results,
his may represent the likely mechanism for limited neoin-
imal growth at later time points.
In summary, our data indicate a crucial role of v3-
ntegrins for the homing of EPCs to injured arterial
egments after stent implantation. Thus, this class of mol-
cules represents a promising target for drug development to
ccelerate healing and reduce restenosis after vascular injury.
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